UNSPSC 51314201: Hypostamine or tritoqualine

This classification denotes a cholagogue, choleretic, histamine h1 antagonist, and phthalic anhydride with the molecular formula C26H32N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4MW5166YH, chemically known as 4,5,6-triethoxy-7-amino-3-(8-methoxy-2-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydro-1-isochinolinyl)phthalid but generally known as tritoqualine, which bears US NIH Compound Identifier 72145.

UNSPSC 51314201 Hypostamine or tritoqualine is a Commodity code that in recent state and local procurement shows little activity directly aligned with its nominal pharmaceutical scope. The recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements — none of which are hypostamine or tritoqualine products. The code's abstract name does not match the work actually being solicited, suggesting either a cataloging mismatch in the source data or that this code is applied inconsistently across state and local procurement systems. State and local buyers using pharmaceutical codes in this family appear to be health departments, state health and human services commissions, and cooperative purchasing alliances seeking to establish supply relationships for controlled substances, OTC products, and pharmaceutical distribution systems.

Geographically, recent activity shows Florida, Texas, and Minnesota as the primary jurisdictions. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023 — though that date appears inconsistent with the posting date. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. The MMCAP procurement is the largest in scope, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. No explicit set-asides or disadvantaged-enterprise designations appear in these opportunities.